SOMERSET, N.J. - January 16, 2020 - Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced the appointment of Karen Flynn as President of Biologics and Chief Commercial Officer. Ms. Flynn has also joined the company`s Executive Leadership Team and will report to Alessandro Maselli, Catalent`s President and Chief Operating Officer. Ms. Flynn takes on the role previously held by Mr. Barry Littlejohns, who will be retiring. Ms. Flynn assumes global responsibility for Catalent`s biologics business, including the several investments and...
|
